Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Caffeine for Excessive Daytime Somnolence in Parkinson's Disease
NCT00459420Phase 3Completed
- Start
- Apr 2007
- Primary completion
- Jul 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Excessive Daytime Sleepiness (EDS) comparing Caffeine with Placebo (2 arms). Primary endpoint: Epworth Sleepiness Scale at 3 weeks. Started Apr 2007; status: completed.
02
Drugs
caffeine
03
Conditions
Excessive Daytime Sleepiness (EDS)
Beyond the preview
Go deeper on NCT00459420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00459420.